Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avecho Biotechnology Limited ( (AU:AVE) ) has provided an update.
Avecho Biotechnology has notified holders of its listed options (ASX: AVEOA) that the options, exercisable at $0.012, will expire at 5:00pm AEST on 10 May 2026, with trading to cease on 4 May 2026. Option holders may choose to exercise all or part of their options before expiry by submitting a notice of exercise and payment, but are under no obligation to do so, a process that could provide additional capital ahead of key clinical milestones.
The company highlighted its focus on a Phase III trial of its CBD TPM soft-gel capsule for insomnia, a large and costly global health issue with a rapidly growing sleep-aids market. Success in this trial could support registration of an over-the-counter CBD insomnia treatment in Australia, where recent regulatory changes and unmet need create a first-mover commercial opportunity for Avecho and its stakeholders.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian biopharmaceutical company that develops and commercialises human and animal health products using its proprietary Tocopheryl Phosphate Mixture (TPM) drug-delivery system. Derived from vitamin E, TPM is designed to enhance the solubility and absorption of drugs and nutrients, with Avecho’s lead asset a CBD TPM soft-gel capsule in Phase III development for insomnia treatment.
Average Trading Volume: 6,215,137
Technical Sentiment Signal: Sell
Current Market Cap: A$40.41M
For detailed information about AVE stock, go to TipRanks’ Stock Analysis page.